Literature DB >> 26658301

Reply to Phillips, Morris, and Walker.

Scott Evans1, Dean Follmann2, David Schoenfeld3, Vance G Fowler4, Henry F Chambers5.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 26658301      PMCID： PMC4772839          DOI： 10.1093/cid/civ1003

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  2 in total

1.  DOOR/RADAR: A Gateway Into the Unknown?

Authors:  Patrick Peter John Phillips; Tim Peter Morris; Ann Sarah Walker
Journal:  Clin Infect Dis       Date:  2015-12-09       Impact factor: 9.079

2.  Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR).

Authors:  Scott R Evans; Daniel Rubin; Dean Follmann; Gene Pennello; W Charles Huskins; John H Powers; David Schoenfeld; Christy Chuang-Stein; Sara E Cosgrove; Vance G Fowler; Ebbing Lautenbach; Henry F Chambers
Journal:  Clin Infect Dis       Date:  2015-06-25       Impact factor: 9.079
  2 in total
  2 in total

1.  Desirability of outcome ranking (DOOR) for comparing diagnostic tools and early therapeutic choices in patients with suspected candidemia.

Authors:  Daniele Roberto Giacobbe; Alessio Signori; Mario Tumbarello; Riccardo Ungaro; Giovanni Sarteschi; Elisa Furfaro; Malgorzata Mikulska; Maurizio Sanguinetti; Brunella Posteraro; Angela Raffaella Losito; Gennaro De Pascale; Valerio Del Bono; Claudio Viscoli
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-11-30       Impact factor: 3.267

2.  Good Studies Evaluate the Disease While Great Studies Evaluate the Patient: Development and Application of a Desirability of Outcome Ranking Endpoint for Staphylococcus aureus Bloodstream Infection.

Authors:  Sarah B Doernberg; Thuy Tien Tram Tran; Steven Y C Tong; Mical Paul; Dafna Yahav; Joshua S Davis; Leonard Leibovici; Helen W Boucher; G Ralph Corey; Sara E Cosgrove; Henry F Chambers; Vance G Fowler; Scott R Evans; Thomas L Holland
Journal:  Clin Infect Dis       Date:  2019-05-02       Impact factor: 9.079
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.